Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
News Topics
- (-) ITER (4)
- (-) Summit (9)
- 3-D Printing/Advanced Manufacturing (26)
- Advanced Reactors (2)
- Artificial Intelligence (7)
- Big Data (5)
- Bioenergy (13)
- Biology (23)
- Biomedical (10)
- Biotechnology (5)
- Buildings (13)
- Chemical Sciences (7)
- Clean Water (8)
- Climate Change (11)
- Composites (6)
- Computer Science (30)
- Coronavirus (10)
- Critical Materials (4)
- Cybersecurity (5)
- Decarbonization (7)
- Energy Storage (22)
- Environment (39)
- Exascale Computing (2)
- Frontier (4)
- Fusion (8)
- Grid (11)
- High-Performance Computing (19)
- Isotopes (12)
- Machine Learning (1)
- Materials (32)
- Materials Science (22)
- Mathematics (1)
- Mercury (3)
- Microscopy (10)
- Nanotechnology (10)
- National Security (7)
- Net Zero (1)
- Neutron Science (18)
- Nuclear Energy (6)
- Physics (3)
- Polymers (5)
- Quantum Computing (5)
- Quantum Science (12)
- Security (3)
- Space Exploration (4)
- Statistics (1)
- Sustainable Energy (35)
- Transportation (21)
Media Contacts
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.
From the helm of a one-of-a-kind organization that brings nuclear fusion and fission expertise together to pave the way to expanding carbon-free energy, Kathy McCarthy can trace the first step of her engineering career back to
Since the 1930s, scientists have been using particle accelerators to gain insights into the structure of matter and the laws of physics that govern our world.